NEONC Technologies

NeOnc Technologies is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system (CNS) diseases. Their innovative approach revolves around overcoming the blood-brain barrier, a natural defense mechanism that often hinders the delivery of drugs to the brain. NeOnc's patented NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods, with their lead products, NEO100 and NEO212, currently in Phase II human clinical trials.

NeOnc's mission is to enhance patient care and bring hope to those battling brain and CNS diseases. They are committed to aggressively pursuing innovative solutions that extend lives. Their focus on research, collaboration with medical professionals, and personalized patient care has driven their success in developing potential treatments for conditions like brain cancer and meningioma. NeOnc is driven by a vision of a world free from the fear of brain cancer, and they are dedicated to transforming the standard of care for CNS diseases.

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative pharma-based therapeutics and drug delivery methods that effectively treat central nervous system (CNS) diseases and disorders. The company's mission is driven by a commitment to finding solutions that enhance patient care, bring hope, and extend lives, ultimately transforming the standard of care for CNS diseases.

NeOnc Technologies promotes a culture of innovation, collaboration, and patient-centricity. The company emphasizes a relentless pursuit of scientific breakthroughs, fostering a close working relationship with medical professionals and researchers. NeOnc's values center around ethical standards and a commitment to providing value and trust to all stakeholders, including the medical community, patients, staff, and stockholders.